UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000061378
Receipt number R000070123
Scientific Title Development of a Three-Dimensional Quantitative Assessment Method for Finger Position in Patients with Post-Stroke Hemiparesis: Examination of Reliability, Validity, and Responsiveness
Date of disclosure of the study information 2026/04/27
Last modified on 2026/04/26 16:44:54

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Study of a New Three-Dimensional Method to Measure Hand and Finger Movements After Stroke

Acronym

3D Finger Study

Scientific Title

Development of a Three-Dimensional Quantitative Assessment Method for Finger Position in Patients with Post-Stroke Hemiparesis: Examination of Reliability, Validity, and Responsiveness

Scientific Title:Acronym

3D-FINGER Study

Region

Japan


Condition

Condition

stroke

Classification by specialty

Rehabilitation medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study is to develop an assessment method using the extended version of Google MediaPipe Hands (GMH-D) to quantitatively evaluate three-dimensional finger positions in patients with post-stroke motor paralysis, and to examine its reliability, validity, and responsiveness.

Basic objectives2

Others

Basic objectives -Others

Development and validation of a three-dimensional assessment method for finger position in patients with post-stroke hemiparesis

Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

Three-dimensional coordinates of the fingers, assessed at baseline and after 3-4 weeks of intervention for responsiveness evaluation

Key secondary outcomes

Fugl-Meyer Assessment upper extremity
modified Ashworth scale


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

120 years-old >

Gender

Male and Female

Key inclusion criteria

1. Age 18 years or older. For the prospective cohort study assessing responsiveness, only first-ever stroke patients will be included.
2. Unilateral cerebral lesion confirmed by imaging findings or physician diagnosis/clinical records.
3. Ability to position the hand so that the fingertips can be captured by the camera during assessment.

Key exclusion criteria

1.Severe finger contracture or spasticity affecting the hand/fingers.
2.Difficulty in communication due to aphasia or impaired consciousness.
3.Severe higher brain dysfunction that interferes with assessment procedures.
4.Severe visual or hearing impairment.
5.Severe psychiatric disorders such as depression or schizophrenia.
6.Contraindications to exercise therapy, including:
a. Severe cardiovascular disease, such as unstable angina, recent myocardial infarction, decompensated congestive heart failure, acute cor pulmonale, uncontrolled arrhythmia, severe aortic stenosis, active myocarditis, or endocarditis.
b. Uncontrolled hypertension.
c. Acute systemic illness or fever.
d. Recent pulmonary embolism, acute cor pulmonale, or severe pulmonary hypertension.
e. Severe hepatic or renal dysfunction.
f. Severe orthopedic disorders interfering with exercise.
g. Severe cognitive impairment or severe psychiatric disorders.
h. Other metabolic disorders (e.g., acute thyroiditis).

Target sample size

125


Research contact person

Name of lead principal investigator

1st name Michiyuki
Middle name
Last name Kawakami

Organization

Keio University School of Medicine

Division name

Department of Rehabilitation Medicine

Zip code

160-8582

Address

35 Shinanomachi, Shinjuku-ku, Tokyo, Japan

TEL

03-5843-6169

Email

michiyukikawakami@a3.keio.jp


Public contact

Name of contact person

1st name Masayuki
Middle name
Last name Dogan

Organization

Keio University School of Medicine

Division name

Department of Rehabilitation Medicine

Zip code

160-8582

Address

35 Shinanomachi, Shinjuku-ku, Tokyo, Japan

TEL

03-5843-6169

Homepage URL


Email

dogan.m@keio.jp


Sponsor or person

Institute

Keio University School

Institute

Department

Personal name

Michiyuki Kawakami


Funding Source

Organization

Japan Agency for Medical Research and Development

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Research Ethics Committee, Keio University School of Medicine

Address

35 Shinanomachi, Shinjuku-ku, Tokyo, Japan

Tel

03-3353-1211

Email

med-rinri-jimu@adst.keio.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 04 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2026 Year 03 Month 30 Day

Date of IRB


Anticipated trial start date

2026 Year 04 Month 27 Day

Last follow-up date

2029 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This study was approved by the Research Ethics Committee of Keio University School of Medicine and registered in UMIN-CTR prior to study initiation.


Management information

Registered date

2026 Year 04 Month 26 Day

Last modified on

2026 Year 04 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000070123